3 completed, 1 recruiting, 1 terminated. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Acute Lymphoblastic Leukemia (ALL): new trials by email Literature Review of Acute Lymphoblastic Leukemia (ALL) trials Research Report on Acute Lymphoblastic Leukemia (ALL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant | Phase 2 / Phase 3 | Recruiting | Bambino Gesù Hospital and Research Institute | 1000 | 2026-01-07 | 2026-10-20 |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS NiCord® (omidubicel), Cord Blood Unit - Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Completed | Gamida Cell ltd | 125 | 2016-12-16 | 2026-02-25 |
| International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 SR-A + Epratuzumab, SR-B + Epratuzumab - Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Completed | Charite University, Berlin, Germany | 700 | 2014-05-01 | 2024-02-09 |
| A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Vincristine Sulfate Liposomes Injection (VSLI), Vincristine Sulfate Injection (VSI) - Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 26 | 2012-03-01 | 2021-09-09 |
| Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL Glucarpidase - Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Completed | Nordic Society for Pediatric Hematology and Oncology | 47 | 2008-07-01 | 2018-09-28 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Myelodysplastic Syndromes (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Leukemia (4) · Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Leukemia, Myeloid (1) · Myeloproliferative Disorders (1)
Adrenal Cortex Hormones (1) · Cyclophosphamide (1) · Receptors, Scavenger (1) · Vincristine (1) · blinatumomab (1) · epratuzumab (1) · glucarpidase (1) · ruxolitinib (1)
Bambino Gesù Hospital and Research Institute (1) · Charite University, Berlin, Germany (1) · Gamida Cell ltd (1) · Nordic Society for Pediatric Hematology and Oncology (1) · Spectrum Pharmaceuticals, Inc (1)
Denmark (3) · Finland (3) · France (3) · Italy (3) · Norway (3) · Austria (2) · Czechia (2) · Germany (2) · Israel (2) · Netherlands (2) · Poland (2) · Portugal (2) · United Kingdom (2) · United States (2) · Australia (1)
Arend von Stackelberg, MD (1) · Franco Locatelli, Professor (1) · Jesper Heldrup, M D (1) · Mitchell Horwitz, MD (1) · Susan M O'Brien, MD (1)
PMID 27966809, PMID 33811823, PMID 34157093, PMID 37120136, PMID 37341952, PMID 37703995
2025 (1)